Efficacy of integrated therapy compared to standalone allopathic management in bronchial asthma in children aged 8 to 16 years.

Efficacy of Virechana and Bharngyadi Avaleha as an add on to Standard of Care in the management of Mild to Moderate Bronchial Asthma (Tamaka Shwasa) in children aged 8-16 years An open labelled Double arm Randomized Controlled Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/111009

Enrollment

Registered

2026-05-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J453- Mild persistent asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Children, of age group of 8 to 16 years irrespective of sex, religion, socioeconomic status. Patient presenting with past history of minimum 4 classical symptoms of Tamaka Shwasa which are mentioned in diagnostic criteria. Mild intermittent or Mild and Moderate persistent asthma (As per GINA 2025)

Exclusion criteria

Exclusion criteria: Severe asthma or life-threatening exacerbations Patients already on daily Asthma preventive medications Other significant chronic respiratory or systemic illnesses or birth defects Contraindications to Panchakarma components Brittle Asthma (H/o need of hospital admission/ 02 supplementation in previous asthma attacks)

Design outcomes

Primary

Measure	Time frame
Change in FEV1, FVC, PEF Change in Asthma Control Test (ACT/C-ACT) scores from baseline. PRAM (Pediatric Respiratory Assessment Measure) (BT, AT) To assess asthma control as per GINA assessment Timepoint: Day 0 and after 12 weeks	—

Secondary

Measure	Time frame
Improvement in Tamaka Shwasa symptoms i.e. Shwasakrichhrata, Ghurghurukam, Kasa, Pinasa, Parshva Shula, Kapha Nishthivana, Kanthodhwansa, Anidra, Ushnabhinanditi (BT, AT) Total frequency of the acute episodes of asthma during last two months (BT, AT) Need of rescue medication Adverse events attributable to Asthma Drugs Improvement in QOL Timepoint: Before and After Treatment and in Follow up	—

Countries

India

Contacts

Public ContactDr Sagar M Bhinde

Institute of Teaching and Research in Ayurveda, Jamnagar

sgrbhinde@gmail.com9662512158

Outcome results